Top Markets
#1 Akedo Akedo +85.57%
#2 TENDIES TENDIES +76.85%
#3 Verus Coin Verus Coin +43.84%
#4 Threshold Network Threshold Network +42.83%
#5 Mubarak Mubarak +30.39%
#6 MultiversX MultiversX +28.68%
#7 Bitway Bitway +24.57%
#8 Cash Cat Cash Cat +23.24%
#9 Palladium Network Palladium Network +22.68%
#10 Wrapped Aave Ethereum USDC Wrapped Aave Ethereum USDC +18.00%
Coin of the day
Akedo Akedo
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
ProQR Therapeutics N.V. ProQR Therapeutics N.V.

ProQR Therapeutics N.V.

PRQR
Kedudukan dalam Saham #17697
ProQR Therapeutics N.V. operates as a biopharmaceutical enterprise dedicated to... ProQR Therapeutics N.V. operates as a biopharmaceutical enterprise dedicated to discovering and developing RNA-based therapies designed to address genetic disorders. The company's pipeline includes two primary drug candidates in advanced clinical stages: Sepofarsen is currently in a Phase II/III clinical trial, known as the ILLUMINATE trial, targeting Leber Congenital Amaurosis 10 (LCA10). Ultevursen is also undergoing Phase II/III evaluation for the treatment of USH2A-mediated retinitis pigmentosa and Usher syndrome. Beyond its clinical programs, ProQR is actively developing its proprietary Axiomer RNA base-editing platform technology. Strategic collaborations are central to ProQR's strategy, evidenced by its licensing agreements with institutions such as Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center. Furthermore, a significant license and research partnership exists with Eli Lilly and Company, focused on the discovery, advancement, and commercialization of novel medicines for genetic conditions impacting the liver and nervous system. Established in 2012, ProQR Therapeutics N.V. maintains its corporate headquarters in Leiden, the Netherlands.
Harga Saham
$2.19
Modal Pasaran
$230.27M
Perubahan (1 hari)
3.14%
Perubahan (1 tahun)
-4.52%
Negara
NL
Perdagangan ProQR Therapeutics N.V. (PRQR)

Kategori

Healthcare
Nisbah P/E bagi ProQR Therapeutics N.V. (PRQR)
Nisbah P/E pada 2026 TTM: 0
Menurut laporan kewangan dan harga saham terkini ProQR Therapeutics N.V., nisbah P/E semasa (TTM) ialah 0. Pada akhir 2026, syarikat mempunyai nisbah P/E sebanyak 0.
Sejarah nisbah P/E bagi ProQR Therapeutics N.V. dari 2026 hingga 2026
Nisbah P/E pada akhir setiap tahun
Tahun Nisbah P/E Ubah
Tidak cukup data untuk tarikh yang disediakan.
Nisbah P/E untuk syarikat serupa atau pesaing
Syarikat Nisbah P/E Perbezaan Nisbah P/E Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 31.44 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 36.85 -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -17.59 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 -23.32 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Cara membaca nisbah P/E

Nisbah Harga/Perolehan (P/E) mengukur hubungan antara harga saham syarikat dan pendapatan sesaham.
P/E yang rendah tetapi positif menunjukkan syarikat menjana keuntungan tinggi berbanding dengan penilaian semasa dan mungkin dinilai rendah. P/E negatif yang tinggi (hampir 0) menunjukkan kerugian besar.

Syarikat dengan P/E melebihi 30 atau negatif biasanya dilihat sebagai "saham pertumbuhan", bermaksud pelabur menjangkakan pertumbuhan atau keuntungan masa depan.

Syarikat dengan P/E positif di bawah 10 biasanya dianggap sebagai "saham nilai", bermaksud syarikat sudah menguntungkan dan tidak dijangka berkembang pesat.